USPTO Art Unit 1635 Prosecution Statistics

Art Unit Information

Art Unit: 1635
Group: 1630
Tech Center: 1600
Total Cases: 10,061
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19054630COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONFebruary 2025April 2025Allow200YesNo
19007236COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONDecember 2024March 2025Allow300YesNo
18933878COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520NoNo
18932078COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18931989COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow510NoNo
18928880CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B (CIDEB) IRNA COMPOSITIONS AND METHODS OF USE THEREOFOctober 2024May 2025Allow610YesNo
18915035EFFICIENT SYNTHESIS AND ASSEMBLY METHOD FOR LARGE FRAGMENT DNA BASED ON PROGRAMMABLE NUCLEASE ARGONAUTEOctober 2024April 2025Allow610NoNo
18886396APOPTOTIC CELL MIMICSeptember 2024April 2025Allow710YesNo
18819737RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of UseAugust 2024March 2025Allow610YesNo
18819435MODELS OF TAUOPATHYAugust 2024April 2025Allow810NoNo
18799447MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYAugust 2024December 2024Allow410NoNo
18797746BIOMARKER FOR PREDICTING DRUG RESISTANCE OF BRUTON'S TYROSINE KINASE INHIBITORS AND APPLICATION THEREOFAugust 2024January 2025Allow510NoNo
18765750SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATIONJuly 2024February 2025Allow710NoNo
18765286RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATIONJuly 2024April 2025Allow920YesNo
18755750CRISPR-CAS13 SYSTEM AND USE THEREOFJune 2024January 2025Allow710YesNo
18741110ANTISENSE OLIGONUCLEOTIDE TARGETING ATN1 MRNA OR PRE-MRNAJune 2024December 2024Allow710YesNo
18739091COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJune 2024January 2025Allow710YesNo
18715637RECOMBINANT COLLAGEN AND PREPARATION METHOD AND USE THEREOFMay 2024May 2025Allow1210YesNo
18673713TRANS-SPLICING MOLECULESMay 2024June 2025Allow1300NoNo
18661339METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHYMay 2024October 2024Abandon510NoNo
18646631APTAMERS FOR BINDING TO A MEMBRANE-BASED LIPIDApril 2024December 2024Allow811NoNo
18630828COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICSApril 2024January 2025Allow1021YesNo
18625829TREATMENT OF MST1 RELATED DISEASES AND DISORDERSApril 2024August 2024Abandon401YesNo
18617486SYSTEMS AND METHODS FOR ASSOCIATING COMPOUNDS WITH PROPERTIES USING CLIQUE ANALYSIS OF CELL-BASED DATAMarch 2024March 2025Allow1220NoNo
18610930RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of UseMarch 2024March 2025Allow1221NoNo
18608025APOPTOTIC CELL MIMICMarch 2024August 2024Allow511YesNo
18606473MRNA TREATMENT NANOPARTICLESMarch 2024September 2024Allow620NoNo
18441280COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERYFebruary 2024April 2025Allow1410NoNo
18435472APTAMER FOR SPECIFICALLY RECOGNIZING SOLUBLE ST2 PROTEIN AND APPLICATION OF THE SAMEFebruary 2024September 2024Allow710YesNo
18416981MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYJanuary 2024June 2024Allow510NoNo
18411750NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTSJanuary 2024April 2024Allow310NoNo
18407780Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellJanuary 2024September 2024Allow810NoNo
18407815Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellJanuary 2024March 2024Allow200NoNo
18408093MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSEJanuary 2024December 2024Abandon1111NoNo
18408431COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNASJanuary 2024July 2024Allow610NoNo
18406159SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATIONJanuary 2024June 2024Allow600NoNo
18406053COMBINATORIAL TARGETED THERAPY METHODSJanuary 2024February 2025Allow1320YesNo
18392181Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) InhibitorsDecember 2023October 2024Allow1010NoNo
18543827MODIFIED NUCLEIC ACIDS, HYBRID GUIDE RNAS, AND USES THEREOFDecember 2023February 2025Allow1410YesNo
18537662Allosteric Conditional Guide RNAs for Cell-Selective Regulation of CRISPR/CasDecember 2023April 2025Allow1610YesNo
18520878SYSTEMS AND METHODS FOR TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF USING INTEGRATED PRIMING SITESNovember 2023March 2025Abandon1601NoNo
18519995COMPOSITIONS AND METHODS FOR EXPRESSING GENES OF INTEREST IN HOST CELLSNovember 2023September 2024Allow1021YesNo
18518014COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDNovember 2023February 2025Allow6040YesNo
18512207Aptamers For Personal Health Care ApplicationsNovember 2023March 2025Allow1620NoNo
18513348FUNCTION GUIDED IN SILICO PROTEIN DESIGNNovember 2023August 2024Allow811YesNo
18511108DNA Monoclonal Antibodies Targeting Influenza VirusNovember 2023May 2025Allow1820NoNo
18509632SYSTEM AND METHOD FOR PREDICTING SUSCEPTIBILITY OF GENUS KLEBSIELLA TO AMIKACINNovember 2023June 2024Allow720NoNo
18507183FACTOR XII (F12) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2023February 2024Allow400NoNo
18504029INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUIDNovember 2023April 2024Abandon501YesNo
18502516MODELS OF TAUOPATHYNovember 2023June 2024Allow700NoNo
18503125SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCERNovember 2023March 2025Allow1620NoNo
18495278RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UseOctober 2023February 2024Allow410NoNo
18493307SYNTHETIC GENOMEOctober 2023April 2025Allow1830NoNo
18381238DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULESOctober 2023December 2024Abandon1401NoNo
18487302KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFOctober 2023March 2025Allow1710NoNo
18487429SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCEROctober 2023November 2024Allow1320NoNo
18481393GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USEOctober 2023November 2024Allow1321YesNo
18479524METHODS AND SYSTEMS FOR USING DEEP LEARNING TO PREDICT PROTEIN-LIGAND COMPLEX STRUCTURES IN PROTEIN FOLDING AND PROTEIN-LIGAND CO-FOLDINGOctober 2023August 2024Allow1011YesNo
18470687CFTR-MODULATING COMPOSITIONS AND METHODSSeptember 2023November 2024Allow1421YesNo
18467297METHOD FOR PRODUCING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN THE SAMESeptember 2023April 2025Allow1920NoNo
18368248APPARATUS, METHOD, AND USE FOR ULTRASOUND MEDIATED MICROBUBBLE DELIVERY OF PHARMACEUTICAL COMPOSITIONSSeptember 2023October 2024Abandon1301NoNo
18464200CIRCULAR RNAS AND PREPARATION METHODS THEREOFSeptember 2023October 2024Allow1411YesNo
18460946NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTSSeptember 2023March 2024Abandon600NoNo
18459180METHOD AND SYSTEM FOR PROVIDING GENETIC INFORMATION ANALYSIS RESULTSAugust 2023June 2025Allow2140YesNo
18239189SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENTAugust 2023April 2025Abandon2010NoNo
18453990METHYLATION-BASED FALSE POSITIVE DUPLICATE MARKING REDUCTIONAugust 2023January 2025Abandon1710YesNo
18452508COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONAugust 2023November 2024Allow1520YesNo
18451322MODIFIED RIBONUCLEIC ACIDS AND USES THEREOFAugust 2023May 2024Allow911NoNo
18234952METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)August 2023April 2025Abandon2010NoNo
18450033VIRAL VECTOR PRODUCTIONAugust 2023February 2025Allow1810NoNo
18233738HOMELAND EXPLOSIVE CONSEQUENCE AND THREAT (HEXCAT) MODELING AND MEDICAL MITIGATION TOOLAugust 2023October 2024Allow1410NoNo
18448254METHODS FOR PRODUCTION OF MSC-DERIVED EXOSOMESAugust 2023June 2025Allow2211NoNo
18231434KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFAugust 2023January 2025Abandon1701NoNo
18362698RNA EDITING VIA RECRUITMENT OF SPLICEOSOME COMPONENTSJuly 2023September 2024Allow1421YesNo
18356404Methods for Treatment of Alport SyndromeJuly 2023October 2024Abandon1510NoNo
18219524BIOCONTAINMENT/BIOCONTROL SYSTEM AND METHODSJuly 2023May 2025Allow2200YesNo
18218155FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) IRNA COMPOSITIONS AND METHODS OF USE THEREOFJuly 2023February 2025Allow2011NoNo
18345653GENE EDITINGJune 2023June 2025Abandon2410NoNo
18345452ANGELMAN SYNDROME ANTISENSE TREATMENTJune 2023September 2024Allow1420NoNo
18215848KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJune 2023January 2025Abandon1810NoNo
18342806P21 MRNA TARGET AREAS FOR SILENCINGJune 2023March 2024Allow811NoNo
18342409CONJUGATED ANTISENSE COMPOUNDS AND THEIR USEJune 2023December 2024Allow1810NoNo
18213289COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSIONJune 2023November 2023Allow500NoNo
18335875SYSTEMS AND METHODS FOR PREDICTING RESULTS OF A MANUFACTURING PROCESS FOR GENERATING BIOLOGICAL STRUCTURESJune 2023July 2024Allow1320YesNo
18334932RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of UseJune 2023December 2023Allow610NoNo
18332464GUIDE RNA WITH CHEMICAL MODIFICATIONSJune 2023January 2025Abandon1921NoNo
18330853AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAMEJune 2023May 2024Allow1121YesNo
18329431SYSTEMS AND METHODS FOR EPIGENETIC ANALYSISJune 2023March 2025Allow2210NoNo
18205390NUCLEOLIN-TARGETING APTAMERS AND METHODS OF USING THE SAMEJune 2023January 2025Allow2011NoNo
18327139HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFJune 2023February 2024Allow810NoNo
18324799SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDSMay 2023August 2024Allow1510NoNo
18322487OLIGONUCLEOTIDES CONJUGATED TO OLEIC ACID AND USES THEREOFMay 2023June 2024Allow1321NoNo
18321475SYNTHETIC GENOMEMay 2023October 2024Abandon1621NoNo
18037065Fluorescent Fusion Based Heterologous Peptide ProductionMay 2023August 2024Allow1520YesNo
18316556Albumin Production and Cell ProliferationMay 2023September 2024Abandon1610NoNo
18316939SYSTEMS AND METHODS FOR GROUPING AND COLLAPSING SEQUENCING READSMay 2023June 2024Allow1410NoNo
18315890MODULATING APOLIPOPROTEIN (A) EXPRESSIONMay 2023April 2025Allow2420NoNo
18316033SYNTHETIC SELF-AMPLIFYING MRNA MOLECULES WITH SECRETION ANTIGEN AND IMMUNOMODULATORMay 2023May 2024Allow1221YesNo
18312821METHOD FOR IMPROVING DISEASE DIAGNOSIS USING MEASURED ANALYTESMay 2023May 2025Abandon2520NoNo
18311484EXTRAHEPATIC DELIVERYMay 2023January 2024Allow921NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1635.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
85
Examiner Affirmed
65
(76.5%)
Examiner Reversed
20
(23.5%)
Reversal Percentile
10.5%
Lower than average

What This Means

With a 23.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
782
Allowed After Appeal Filing
108
(13.8%)
Not Allowed After Appeal Filing
674
(86.2%)
Filing Benefit Percentile
0.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1635 - Prosecution Statistics Summary

Executive Summary

Art Unit 1635 is part of Group 1630 in Technology Center 1600. This art unit has examined 10,061 patent applications in our dataset, with an overall allowance rate of 49.5%. Applications typically reach final disposition in approximately 31 months.

Comparative Analysis

Art Unit 1635's allowance rate of 49.5% places it in the 6% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1635 receive an average of 1.72 office actions before reaching final disposition (in the 41% percentile). The median prosecution time is 31 months (in the 36% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.